Related Experiment Videos
Radioisotopes for metastatic bone pain
M Roqué1, M J Martinez, P Alonso
1Service of Epidemiology and Public Health. Iberoamerican Cochrane Centre, Hospital de la Santa Creu i Sant Pau, c/ Sant Antoni M. Claret 171, 4a planta 08041, Barcelona, Cataluña, Spain. mroque@hsp.santpau.es
The Cochrane Database of Systematic Reviews
|October 30, 2003
Summary
Radioisotopes offer some pain relief for bone metastases over one to six months, but can cause side effects like leukocytopenia. Further research is needed for long-term efficacy and safety in metastatic bone pain management.
Area of Science:
- Oncology
- Radiopharmaceuticals
- Pain Management
Background:
- Bone metastases frequently cause pain and complications like fractures and spinal cord compression.
- Current pain management strategies include cancer treatment, radiotherapy, analgesics, and bone-targeting agents.
- Radioisotopes are among the agents used to manage bone metastases and associated pain.
Purpose of the Study:
- To evaluate the effectiveness of radioisotopes in controlling metastatic bone pain.
- To assess the impact of radioisotopes on bone metastasis complications such as hypercalcemia, fractures, and spinal cord compression.
- To determine the effects of radioisotopes on patient survival and identify any adverse events.
Main Methods:
- Systematic review of randomized controlled trials (RCTs) identified through MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials.
- Inclusion criteria focused on RCTs comparing radioisotopes with placebo for metastatic bone pain, assessing pain or complications at least four weeks post-treatment.
- Study quality was evaluated using the Jadad scale and Oxford Pain Validity Score, with data extracted by two independent reviewers and analyzed using a random effects model.
Main Results:
- Four RCTs involving 325 patients indicated a modest short- to medium-term (1-6 months) pain reduction with radioisotopes.
- No significant difference in analgesic use was observed between radioisotope and placebo groups.
- Radioisotope administration was associated with a significantly higher incidence of leukocytopenia and a non-significant increase in thrombocytopenia.
Conclusions:
- Radioisotope efficacy for metastatic bone pain is supported by limited evidence from small, short-term trials.
- While radioisotopes may provide pain relief without increasing analgesic needs, potential adverse effects like leukocytopenia and thrombocytopenia must be considered.
- Further research with larger sample sizes and longer follow-up periods is warranted to fully elucidate the long-term benefits and risks of radioisotopes in managing bone metastases.